EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents

Kacper Żełabowski, Wiktor Petrov, Kacper Wojtysiak iD, Zuzanna Ratka iD, Kamil Biedka iD, Michał Wesołowski iD, Katarzyna Fus, Dawid Ślebioda iD, Malwina Rusinek, Maria Sterkowicz iD, Izabela Radzka iD, Agnieszka Chłopaś-Konowałek

International Journal of Molecular Sciences · 06.09.2025 · 26 (17) · 8700

DOI: 10.3390/ijms26178700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.09.2025. Verfasst von Kacper Żełabowski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wrocl…. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Triazoles, Orexin Receptor Antagonists, Orexins. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The orexin (hypocretin) system plays a central role in regulating the sleep–wake cycle through two neuropeptides, orexin-A and orexin-B, which act on OX1R and OX2R receptors. Emerging evidence links heightened orexin signaling with the pathophysiology of chronic insomnia. This review outlines the neurobiology of the orexinergic system, compares the pharmacological profile of dual orexin receptor antagonists (DORAs) to traditional GABAergic hypnotics, and evaluates the clinical efficacy and safety of Suvorexant, Lemborexant, and Daridorexant. DORAs function by selectively dampening orexin-driven arousal, thereby facilitating sleep onset and maintenance without disrupting natural sleep architecture. Clinical trials have shown that these agents significantly reduce sleep latency and enhance sleep continuity, with a favorable side effect profile. Overall, DORAs represent a distinct and clinically advantageous option for insomnia treatment, with growing interest in their potential utility across mood, anxiety, and neurodegenerative disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersTriazolesOrexin Receptor AntagonistsOrexinsHumansAzepinesAnimalsPyrimidinesOrexin ReceptorsPyrrolidinesImidazolesPyridines

Stichwörter der Autor:innen

daridorexantdual orexin receptor antagonists (DORAs)hypocretininsomnialemborexantorexin systempsychopharmacotherapysleep architecturesuvorexant

Substanzen

suvorexantAzepinesTriazolesOrexin Receptor AntagonistsOrexinslemborexantdaridorexantPyrimidinesOrexin ReceptorsPyrrolidines

Autor:innen und Institutionen

  • Scientific Society for Psychopharmacology, Department of Forensic Medicine, Wroclaw Medical University, 4 J. Mikulicza-Radeckiego Street, 50345 Wroclaw, Poland.
  • Department of Physiology and Pathophysiology, Division of Pathophysiology, Wroclaw Medical University, Chalubinskiego 10, 50368 Wroclaw, Poland.
  • Department of Forensic Medicine, Division of Molecular Techniques, Faculty of Medicine, Wroclaw Medical University, Sklodowskiej-Curie 52, 50369 Wroclaw, Poland.

ORCID-Profile: Kacper Wojtysiak, Zuzanna Ratka, Kamil Biedka, Michał Wesołowski, Dawid Ślebioda, Maria Sterkowicz, Izabela Radzka

Zitieren

APA

Żełabowski, K., Petrov, W., Wojtysiak, K., Ratka, Z., Biedka, K., Wesołowski, M., Fus, K., Ślebioda, D., Rusinek, M., Sterkowicz, M., Radzka, I., & Chłopaś-Konowałek, A. (2025). Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents. International Journal of Molecular Sciences, 26(17), 8700. https://doi.org/10.3390/ijms26178700

Vancouver

Żełabowski K, Petrov W, Wojtysiak K, Ratka Z, Biedka K, Wesołowski M, et al. Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents. International Journal of Molecular Sciences. 2025;26(17):8700. doi:10.3390/ijms26178700

BibTeX
@article{eabowski2025,
  author = {Żełabowski, Kacper and Petrov, Wiktor and Wojtysiak, Kacper and Ratka, Zuzanna and Biedka, Kamil and Wesołowski, Michał and Fus, Katarzyna and Ślebioda, Dawid and Rusinek, Malwina and Sterkowicz, Maria and Radzka, Izabela and Chłopaś-Konowałek, Agnieszka},
  title = {Targeting the Orexin System in the Pharmacological Management of Insomnia and Other Diseases: Suvorexant, Lemborexant, Daridorexant, and Novel Experimental Agents},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {17},
  pages = {8700},
  doi = {10.3390/ijms26178700}
}
Kostenlos starten →